- Home
- ANIX vs COEP Comparison
ANIX vs COEP Comparison
Compare ANIX & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- COEP
- Stock Information
- Founded
- ANIX 1982
- COEP 2017
- Country
- ANIX United States
- COEP United States
- Employees
- ANIX N/A
- COEP N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANIX Health Care
- COEP Health Care
- Exchange
- ANIX Nasdaq
- COEP Nasdaq
- Market Cap
- ANIX 95.7M
- COEP 86.0M
- IPO Year
- ANIX 1987
- COEP N/A
- Fundamental
- Price
- ANIX $4.33
- COEP $15.04
- Analyst Decision
- ANIX Strong Buy
- COEP
- Analyst Count
- ANIX 3
- COEP 0
- Target Price
- ANIX $9.00
- COEP N/A
- AVG Volume (30 Days)
- ANIX 293.4K
- COEP 45.2K
- Earning Date
- ANIX 09-10-2025
- COEP 11-12-2025
- Dividend Yield
- ANIX N/A
- COEP N/A
- EPS Growth
- ANIX N/A
- COEP N/A
- EPS
- ANIX N/A
- COEP N/A
- Revenue
- ANIX N/A
- COEP $263,555.00
- Revenue This Year
- ANIX N/A
- COEP N/A
- Revenue Next Year
- ANIX N/A
- COEP N/A
- P/E Ratio
- ANIX N/A
- COEP N/A
- Revenue Growth
- ANIX N/A
- COEP N/A
- 52 Week Low
- ANIX $2.07
- COEP $2.31
- 52 Week High
- ANIX $4.98
- COEP $19.19
- Technical
- Relative Strength Index (RSI)
- ANIX 59.48
- COEP 48.60
- Support Level
- ANIX $3.95
- COEP $14.76
- Resistance Level
- ANIX $4.38
- COEP $16.45
- Average True Range (ATR)
- ANIX 0.36
- COEP 0.84
- MACD
- ANIX -0.03
- COEP -0.22
- Stochastic Oscillator
- ANIX 36.89
- COEP 18.67
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.